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http://www.biomedcentral.com/1472-6882/13/333RESEARCH ARTICLE Open AccessAqueous extracts of Liriope platyphylla induced
significant laxative effects on loperamide-induced
constipation of SD rats
Ji Eun Kim1, Young Ju Lee1, Moon Hwa Kwak1, Jun Ko1, Jin Tae Hong2 and Dae Youn Hwang1,3*Abstract
Background: Liriope platyphylla has long been reported as a therapeutic drug for treatment of various human
chronic diseases including inflammation, diabetes, neurodegenerative disorders, obesity, and atopic dermatitis. To
investigate the laxative effects of L. platyphylla, alterations in excretion parameters, histological structure, mucin
secretion, and related protein levels were investigated in rats with loperamide (Lop)-induced constipation after
treatment with aqueous extract of L. platyphylla (AEtLP).
Methods: Alterations on constipation phenotypes were measured in rats with Lop-induced constipation after
treatment with AEtLP using excretion parameter analysis, histological analysis, RT-PCR, western blot and transmission
electron microscope (TEM) analysis.
Results: The amounts of stool and urine excretion were significantly higher in the Lop + AEtLP-treated group than in
the Lop + vehicle-treated group, whereas food intake and water consumption were maintained at constant levels.
AEtLP treatment also induced an increase in villus length, crypt layer, and muscle thickness in the constipation model.
Total mucin secretion was higher in the Lop + AEtLP-treated group than in the Lop + vehicle-treated group, although
mucin secretion per crypt was very similar among all groups. Furthermore, RT-PCR and western blot revealed a
dramatic reduction of key factors level on the muscarinic acetylcholine receptors (mAChRs) signaling pathway in the
Lop + AEtLP-treated group relative to the Lop + vehicle-treated group. Especially, the accumulation of lipid droplets in
enterocytes of crypts following Lop treatment was improved to the level of the No-treated group in response to AEtLP
treatment.
Conclusion: These results suggest that AEtLP improves constipation induced by Lop treatment through an increase in
crypt layer and stimulation of lipid droplet secretions. These data are the first to show that the laxative effects of AEtLP
are closely related to the down-regulation of mAchRs and their downstream signals.Background
Constipation is a chronic gastrointestinal disorder charac-
terized by symptoms such as infrequent bowel movements,
difficulty during defecation, and sensation of incomplete
bowel evacuation [1-3]. Constipation is often caused by
insufficient dietary fiber intake, inadequate fluid intake,
decreased physical activity, side effects of medication,
hypothyroidism, and obstruction by colorectal cancer [4].* Correspondence: dyhwang@pusan.ac.kr
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reproduction in any medium, provided the orVarious chemical drugs such as senna, correctol, exlax,
senokot, and gaviscon are commonly used to treat con-
stipation, although their use is limited due to high costs
and undesirable side effects [5,6]. To date, regulation of
the motility of the gastrointestinal tract has been the
main focus of constipation treatments. Cisapride was
first developed as a promotility agent for treatment of
gastric disease, but was later withdrawn because it in-
creased the risk of cardiac arrhythmias [7,8]. Tegaserod,
a selective 5-hydroxytryptamine receptor antagonist, is
widely used for the treatment of constipation even
though it causes coronary artery contraction, coronary
spasms, and myocardial infarction [9].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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properties based on their ability to increase intestinal
motility, frequency and weight of stools and ileum
tension. Extract of Aloe ferox Mill. has been shown to
improve intestinal motility, increase fecal volume, and
normalize the body weight of loperamide-induced con-
stipated rats [6]. Moreover, ethanol extracts of agarwood
(Aquilaria sinensis, Aquilaria crasna) leaves are known
to increase the frequency and weight of stools, gastro-
intestinal transit, and intestinal tension without induc-
tion of diarrhea as a side effect [10]. Significant increases
in the number, weight, and water content of fecal pellets
as well as the intestinal transit length and thickness of
the distal colon have also been observed in response to
Ficus carica paste treatment [11]. Various herbal medi-
cines have recently received attention as novel thera-
peutic drugs for treatment of constipation.
L. platyphylla is a traditional herbal medicine that has
long been used for the treatment of asthma as well as
bronchial and lung inflammation [12,13]. L. platyphylla is
also known to potently inhibit airway inflammation and
hyperresponsiveness in a murine model of asthma by
modulating the relationship between Th1/Th2 cytokine
imbalance [13] and atopic dermatitis induced by phthalic
anhydride treatment [14,15]. Significant alteration of nerve
growth factor (NGF) secretion and its related signaling
pathway involving NGF receptors TrkA and p75NTR has
been observed in extracts and compounds isolated from
L. platyphylla-treated PC12 cells [16,17]. L. platyphylla
has also demonstrated potential for the treatment of
obesity and diabetes [18,19]. Gyeongshingangjeehwan,
which is primarily composed of L. platyphylla, has been
reported to prevent obesity and hypertriglyceridemia
through the inhibition of feeding and activation of hep-
atic peroxisome proliferator-activated receptor-alpha in
OLETF male rats [19]. Specifically, the homoisoflavone-
enriched and LP9M80-H methanol fractions signifi-
cantly induced insulin secretion and glucose transporter
expression through the mitogen-activated protein kin-
ase (MAPK) signaling pathway [18,20]. It is also well
known that the roots and extract of L. platyphylla contain
a wide variety of constituents, although more analyses are
needed to verify the correlation between their functions
and therapeutic effects. The dry roots of L. platyphylla pri-
marily consist of carbohydrates (6.89 g/100 g) and sodium
(Na; 6.32 g/100 g), as well as proteins, fat and sugar, while
saturated fat, trans-fat and cholesterol are not present.
AEtLP extracted from L. platyphylla roots contained total
saponins (0.56 mg/ml), total soluble solid (31.1 mg/ml),
total sugar (15.9 mg/ml), reducing sugar (1.1 mg/ml) and
total protein (3.2 mg/ml) [15]. In Korea, the effects of
L. platyphylla roots on constipation have been recorded in
Dong-ui-bo-gam, a medical encyclopedia compiled by the
royal physician Heo Jun in 1613, which is on the UNESCOMemory of the World Register [21]. However, scientific
evidence of the correlation between L. platyphylla roots
and constipation have not been presented to date. There-
fore, it is worth investigating the laxative effects of AEtLP
using an animal model for constipation to verify their
mechanism of action under physiological conditions.
Accordingly, the present study was conducted to in-
vestigate the laxative effects of AEtLP on Lop-induced
constipation in SD rats. The data presented here consti-
tute strong evidence that AEtLP extract is a powerful
candidate for alleviation of constipation.
Methods
Preparation of AEtLP
The plant materials of L. platyphylla were collected from
plantations in the Miryang area of Korea at June 2011 and
identified by Dr. Cha Shin Woo at the Herbal Crop
Research Division, National Institute of Horticultural &
Herbal Science. Voucher specimens (WPC-11-010) were
deposited at the Functional Materials Bank of the PNU-
Wellbeing RIS Center in Pusan National University.
Firstly, their roots were dried using a hot-air drier (JSR In-
struments, Uttaranchal, India) at 60°C. Six hundred grams
of dry roots were reduced to powder using an electric
blender and then extracted in 2 L of distilled water, after
which the water extract was purified at 100°C for 2 h using
circulating extraction equipment (IKA Labortechnik,
Staufen, Germany). The calories and main composition of
AEtLP had have been measured in previous studies
[14,22]. Extract solutions were concentrated into dry pel-
lets using a rotary evaporator (EYELA, Tokyo, Japan) and
stored at −80°C until use.
Care and use of animals
The animal protocol used in this study was reviewed
and approved based on ethical procedures and scientific
care by the Pusan National University-Institutional Ani-
mal Care and Use Committee (PNU-IACUC; Approval
Number PNU-2012-0010). Adult SD rats were pur-
chased from SamTacho (Osan, Korea) and handled at
the Pusan National University Laboratory Animal Re-
sources Center according to the National Institutes of
Health guidelines. All rats were provided with standard
irradiated chow diet (Purina Mills, Seoungnam, Korea)
ad libitum and were maintained in a specific pathogen-
free state under a strict light cycle (lights on at 06:00 h
and off at 18:00 h) at a temperature of 22 ± 2°C and a
relative humidity of 50 ± 10%.
Induction of constipation and experimental design
Constipation was induced in SD rats by subcutaneous
injection of loperamide (4 mg/kg weight) in 0.9% sodium
chloride twice a day for 3 days, whereas the non-
constipation group was injected with 0.9% sodium chloride
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were assigned to either a non-constipation group (n = 12)
or a constipation group (n = 12). The non-constipation
group was further divided into a No-treated group (n = 6)
and an AEtLP-treated group (n = 6). The No-treated group
was untreated during the experimental period, whereas the
AEtLP-treated group received 15 μl/g body weight of
AEtLP (1,000 mg/kg weight) one time. The constipation
group was further divided into a Lop + vehicle-treated
group (n = 6) and Lop +AEtLP-treated group (n = 6). The
Lop + vehicle-treated group received a consistent volume of
water via gavage, whereas the Lop +AEtLP cotreatment
group received 15 μl/g body weight of AEtLP (1,000 mg/kg
weight) one time after the induction of constipation. At
24 h after the AEtLP and vehicle treatment, all animals
were sacrificed using CO2 gas and tissue samples were ac-
quired and stored in Eppendorf tubes at −70°C until assay.
Analysis of food intake, water intake, and body weight
Alterations in food intake, water intake, and body weight
were measured daily at 10:00 am throughout the experi-
mental period using an electrical balance and a measur-
ing cylinder. All measurements were performed three
times to ensure accuracy.
Measurement of stool parameters and urinary volume
All SD rats were bred in metabolic cages during the
experimental period to avoid contamination. The stools
and urine excreted from each SD rat were collected at
10:00 am. Stool weight was weighed three times per
sample using an electric balance, whereas the water
content was determined as the difference between the
wet and dry weights of the stool as described previously
[6,11]. Changes in the urine volume were measured
three times per sample using a cylinder.
RT-PCR
The frozen transverse colons were chopped with scissors
and homogenized in RNAzol B solution (Tet-Test Inc.,
CS104). The concentration of isolated RNA was then
determined by UV-spectroscopy. The expression of the
genes was then examined by RT-PCR using 5 μg of the
total RNA from each tissue. Briefly, 500 ng of oligo-dT
primer [Gibco BRL(18418–012)] was annealed with the
template RNA at 70°C for 10 min. The complementary
DNA, which served as the template for subsequent amp-
lification, was then synthesized by adding dATP, dCTP,
dGTP and dTTP with 200 units of reverse transcriptase
and 10 pmole of sense and antisense primers. Next,
amplification was conducted by subjecting the samples
to 28 cycles of 30 sec at 94°C, 30 sec at 62°C and 45 sec
at 72°C in a Perkin-Elmer Thermal Cycler. In each case,
negative-RT controls were included to differentiate the
DNA and RNA products. RT-PCR was also performedusing primers specific to β-actin to ensure the RNA
integrity. The primer sequences used to evaluate M2
expression were as follows: sense primer, 5′-CCAGT
ATCTC CAAGT CTGGT GCAAG G-3′, antisense pri-
mer, 5′-GTTCT TGTAA CACAT GAGGA GGTGC-3′.
Also, the primer sequences used to evaluate M3 expres-
sion were as follows: sense primer, 5′-GTCAC TTCTG
GTTCA CCACC AAGAG C-3′, antisense primer, 5′-
GTGTT CACCA GGACC ATGAT GTTGT AGG-3′.
The sequences of the β-actin sense and antisense
primers were 5′-TGGAA TCCTG TGGCA TCCAT
GAAAC-3′ and 5′-TAAAA CGCAG CTCAG TAACA
GTCCG-3′, respectively. The level of the PCR products
was quantified using a Kodak Electrophoresis Documen-
tation and Analysis System 120 and 1% agarose gels.
Western blotting
Proteins collected from the transverse colon of No-,
AEtLP-, Lop + vehicle- and Lop +AEtLP-treated rats
were separated by 4%–20% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) for 3 h,
after which the resolved proteins were transferred to nitro-
cellulose membranes for 2 h at 40 V. Each membrane was
then incubated separately with primary antibody, anti-
PI-3K (Cell Signaling Technology Inc., Cambridge, MA,
USA), anti-PKC (Cell Signaling Technology Inc.) or anti-
actin (Sigma-Aldrich, Saint Louis, MO, USA) overnight at
4°C. Next, the membranes were washed with washing buf-
fer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, and 0.05% Tween 20) and incubated with horse-
radish peroxidase-conjugated goat anti-rabbit IgG (Zymed
Laboratories, South San Francisco, CA, USA) at a dilution
of 1:1,000 and room temperature for 2 h. Finally, the
membrane blots were developed using Chemilumines-
cence Reagent Plus kits (Pfizer, New York, NY, USA and
Pharmacia, New York, NY, USA).
Histological analysis
Transverse colons collected from SD rats were fixed
with 10% formalin for 12 h, embedded in paraffin wax,
and then sectioned into 5 μm thick slices that were
stained with hematoxylin & eosin (H&E, Sigma-Aldrich,
MO, USA). Morphological features of these sections
were observed under light microscopy, after which the
villus length, crypt thickness, and muscle thickness were
measured using Leica Application Suite (Leica Microsys-
tems, Switzerland).
For mucin staining, transverse colons collected from rats
were fixed with 10% formalin for 48 h, embedded in paraf-
fin wax, and then sectioned into 3 μm thick slices that were
subsequently deparaffinized with xylene and rehydrated.
Next, the samples were rinsed with distilled water and
stained with an Alcian blue stain kit (IHC WORLD, MD,























Figure 1 Effects of AEtLP on body and feeding behavior in
Lop-induced constipated rats. Body weight (A), food intake (B),
and water consumption (C) were measured at the same time during
the experiment. Five to six rats per group were assayed in triplicate
for body weight and feeding behavior analysis. Data represent
the mean ± SD from three replicates. a, p < 0.05 compared to the
No-treated group. b, p < 0.05 compared to the AEtLP-treated group.
c, p < 0.05 compared to the Lop + vehicle-treated group.
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of the crypts were measured using Leica Application
Suite (Leica Microsystems, Switzerland).
TEM analysis
The transverse colons collected from rats were fixed in
2.5% glutaraldehyde in 1x PBS buffer, washed, dehydrated
with ascending concentrations of ethanol, incubated in 1%
OsO4 for 1 h at room temperature, and then embedded in
Epon812 media (Polysciences, Inc., Germany). Ultra-thin
sections (70 nm) were subsequently collected on holy for-
mvar coated grids, contrasted with uranyl acetate and lead
citrate, and examined by TEM (Hitachi, Japan).
Statistical analysis
One-way ANOVA (SPSS for Windows, Release 10.10,
Standard Version; SPSS, Chicago, IL, USA) was used to
determine whether or not significant differences existed
between the AEtLP-treated and vehicle-treated groups
or between the non-constipation and constipation
groups. All values are reported as the mean ± SD. A
P value of < 0.05 was considered significant.
Results
Body weight and feeding conditions of the constipation
rats
Body weight did not differ significantly among experi-
mental groups on day 5 (No-treated group; 298 g,
AEtLP-treated group; 305 g, Lop + vehicle-treated group;
307 g, Lop + AEtLP-treated group; 302 g), although the
Lop + AEtLP-treated group showed a slightly lower body
weight than the other groups (Figure 1A). Moreover, SD
rats with constipation ate significantly less food than the
non-constipation group, while there were no differences
between the Lop + vehicle- and Lop + AEtLP-treated
groups (Figure 1B). Water consumption also did not
change in the constipation group or non-constipation
group. Furthermore, no significant increase in water
consumption was detected in the Lop + AEtLP-treated
group (Figure 1C). Taken together, these results show
that AEtLP treatment did not induce any alteration of
body weight, food intake or water consumption.
Stool and urine excretion
The effects of any treatment on constipation are generally
determined based on altered excretion from laboratory an-
imals. To investigate the laxative effects of AEtLP on stool
and urine excretion, alterations in excretion parameters
were measured in No-, AEtLP-, Lop + vehicle- and Lop +
AEtLP-treated SD rats. Excretion volumes of stool and
urine were significantly reduced after administration of
Lop, while they increased slightly in the AEtLP-treated
group. However, these levels in the Lop +AEtLP-treated
group were almost recovered to those in the No-treatedgroup (Figure 2A, B and D). Indeed, the weight of stool in
the Lop +AEtLP-treated group was approximately twice
that of the No-treated group (Figure 2B). Furthermore, the
water content of stool in the Lop + vehicle-treated group
was roughly 45-55% lower than that in the No-treated
group. However, after Lop and AEtLP cotreatment this
level was elevated significantly to that of the No-treated
group (Figure 2C). These results suggest that AEtLP treat-
ment could improve Lop-induced constipation in SD rats
through enhancement of stool and urine excretion.
Histological alteration of transverse colon
To investigate whether AEtLP treatment could induce





























Figure 2 Effects of AEtLP on stool and urine secretion in
Lop-induced constipated rats. Stool number (A), stool weight
(B), and urine volume (D) were measured immediately using an
electric balance and measuring cylinder. Water content of stools
(C) was determined by drying stools for 12 h. Five to six rats per
group were assayed in triplicate for excretion analysis. Data
represent the mean ± SD from three replicates. a, p < 0.05 compared
to the No-treated group. b, p < 0.05 compared to the AEtLP-treated
group. c, p < 0.05 compared to the Lop + vehicle-treated group.
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thickness were measured in transverse colons of rats in the
three groups following H&E staining. The average length
of the villus was significantly shorter in the Lop + vehicle-
treated group than the No-treated group. Following Lop
and AEtLP cotreatment, this level greatly increased by
more than 60% when compared with the Lop + vehicle-
treated group (Figure 3A and B). Furthermore, alteration
of crypt layer thickness and muscle thickness was very
similar to that of villus length. In the Lop + vehicle-treated
group, the crypt layer thickness and muscle thickness were
dramatically reduced when compared with those in the
No-treated group. However, in the Lop +AEtLP-treated
group, thickness levels were recovered to those in the No-
treated group, although the thickness of the crypt layer in-
creased by 30-35% relative to that of the No-treated group
(Figure 3A and B). These results show that AEtLP induced
increases in villus length, crypt layer thickness, and muscle
thickness in the transverse colon of constipated SD rats.
Effect of AEtLP treatment on mucin secretion
Lop-induced constipation has been shown to induce a
decrease in mucus production from crypt epithelial cells
[23]. To evaluate the effects of AEtLP treatment on mucin
production, we measured the level of mucin production in
Lop-induced constipation rats after AEtP treatment. The
total level of mucin was reduced significantly in the Lop +
vehicle-treated group relative to that in the No-treated
group, while these levels were dramatically recovered to
up to 70-80% of those in the No-treated group after Lop
and AEtLP cotreatment. However, these changes were due
to alteration of crypt layer thickness rather than alteration
of secretion level per crypt (Figure 3C). Overall, these
findings indicate that AEtLP treatment may induce an
increase in total mucin secretion from villus region, al-
though the level of mucin secretion per crypt remained
nearly unchanged.
Effect of AEtLP treatment on expression of mAchRs and
their downstream proteins
Little is known about the proteins associated with consti-
pation, although mAchR M2 and M3 has been reported to
play a role in the contraction of smooth muscle [24]. To
investigate whether AEtLP treatment could affect the
regulation of proteins related to muscle contraction, alter-
ation of mAchR M2, mAchR M3, PI-3K and PKC expres-
sion was observed in the transverse colons of constipation
rats using specific primers and antibody. The expression
patterns of these four factors were very similar among all
groups. RT-PCR analysis revealed that the levels of
mAchR M2 and M3 transcripts in the AEtLP-treated
group increased by 212% and 280% relative to those in the
No-treated group. Following Lop treatment, these levels
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Figure 3 Effects of AEtLP on histological parameters and mucin secretion in Lop-induced constipated rats. (A) H&E-stained sections of
transverse colons rats from the No-treated group (a and b), AEtLP-treated group (c and d), Lop + vehicle-treated group (e and f), or Lop + AEtLP-treated
group (g and h) were observed at two different magnifications using a light microscope. (B) Villus length, crypt layer thickness, and muscle thickness
are presented as graphs. (C) Mucin secretion from transverse colon. Blue indicates mucin stained with alcian blue at pH 2.5. Five to six rats per group
were assayed in triplicate by H&E and alcian blue staining. Data represent the mean ± SD from three replicates. a, p < 0.05 compared to the No-treated
group. b, p < 0.05 compared to the AEtLP-treated group. c, p < 0.05 compared to the Lop + vehicle-treated group.
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Furthermore, the band intensities for PI-3 K and PKC, a
member of the downstream pathway of mAchR M2 and
M3, were in good agreement with the RT-PCR results.
The Lop + vehicle-treated group displaying symptoms
of constipation showed higher expression of PI-3K and
PKC proteins in the transverse colon than the No-
treated group. However, the expression levels of PI-3K
and PKC in the Lop + AEtLP-treated group were recov-
ered to those in the No-treated group (Figure 4B).
Taken together, these results suggest that the laxative
effects induced by AEtLP treatment are correlated with
the down-regulation of mAchRs and their downstreamsignal in the transverse colons of constipated SD rats
induced by Lop treatment.
Effect of AEtLP treatment on ultrastructure of the
transverse colon
To investigate the effects of AEtLP treatment on the
ultrastructure of the transverse colon, ultrastructural
changes in cells and organelles were detected by TEM
analysis. In the No-treated group, the Crypt of Lieber-
kuhn showed a ring structure in which enterocytes,
goblet cells, and paneth cells surrounded a lumen at the
center. This structure in the AEtLP-treated group was
similar to that of the non-treated group, although the
M2
actin
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Figure 4 Level of mAChR and their downstream signal. Alteration of the level of mAChR M2 and M3 transcripts was measured by RT-PCR
(A), while PI-3 K and PKC level was determined using Western blot (B). The level of mAChR M2 and M3 transcripts in transverse colons was
measured by RT-PCR using specific primers. After the intensity of each band was determined using an imaging densitometer, the relative levels
of PI-3 K and PKC protein were calculated based on the intensity of actin protein. Five to six rats per group were assayed in triplicate by RT-PCR
and Western blotting assays. Data represent the mean ± SD of three replicates. a, p < 0.05 compared to the No-treated group. b, p < 0.05
compared to the AEtLP-treated group. c, p < 0.05 compared to the Lop + vehicle-treated group.
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treated group. Following Lop treatment, the ultrastructure
of the crypt changed dramatically in every aspect. The
diameter of the crypt lumen was also smaller in the Lop +
vehicle-treated group than in the No-treated group,
although Lop +AEtLP treatment did not induce anysignificant alteration of lumen diameter (Figure 5A and Ba).
Furthermore, changes in the number of paneth cells were very
similar to those in the lumen diameter (Figure 5A and Bb).
However, Lop + AEtLP treatment had a significant effect
on the number of lipid droplets in the lumen. The crypt
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Figure 5 TEM image of transverse colon. A. The ultrastructure of the crypt in the No-, AEtLP-, Lop + vehicle-, and Lop + AEtLP-treated group was
viewed by TEM at x1800 or x3000 magnification. B. Diameter of crypt lumen (a), the number of paneth cells (b) and lipid droplets
(c) were measured using Leica Application Suite (Leica Microsystems, Switzerland). Five to six rats per group were assayed in triplicate by TEM analysis.
Data represent the mean ± SD from three replicates. a, p < 0.05 compared to the No-treated group. b, p < 0.05 compared to the AEtLP-treated group.
c, p < 0.05 compared to the Lop + vehicle-treated group. Lm, lumen of crypt; Gb, goblet cells; Pn, paneth cells; Gr, granule cells; Ld, lipid droplets;
Nu, nucleus; Mt, mitochondria.
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treated group. Conversely, high accumulation of lipid
droplets was detected in the crypt lumen of the Lop +
AEtLP-treated group. This was especially true in the Lop
+ vehicle-treated group, where the abundance of lipid
droplets and granules increased greatly in enterocytes or
paneth cells, while the levels in goblet cells remained the
same. In the Lop +AEtLP-treated group, the lipid droplets
and granules clearly disappeared from enterocytes and
paneth cells (Figure 5A and Bc). The cells in the Lop +AEtLP-treated group were also more round and broad
than those in the No-treated group (Figure 5A). These
results show that AEtLP effectively restored alteration of
the ultrastructure, including increasing the abundance of
lipid droplets and granules in the crypt of the transverse
colons of constipated rats.
Discussion
Herbal plants and medicinal foods have recently received
increased attention as novel therapeutic drugs for the
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[10,11,25]. In an effort to develop and investigate drugs for
the treatment of constipation, we investigated the thera-
peutic effects of AEtLP on Lop-induced constipated SD
rats. The results clearly demonstrated that AEtLP has
laxative effects, including elevation of stool and urine vol-
umes and the recovery of histological changes induced by
Lop in the transverse colon. Our data are the first to
demonstrate that the laxative effects of AEtLP are tightly
correlated with the down-regulation of mAchRs and their
downstream signal, alteration of the ultrastructure, and
mucin secretion in the transverse colon.
Several chemical compounds including Lop and mor-
phine are widely applied to induce constipation in labo-
ratory animals. Among these, Lop is well known to
stimulate the extension of stool evacuation time and the
delay of intestinal luminal transit through inhibition of
water secretion [26] and smooth movement in the intes-
tinal wall [27,28]. Furthermore, Lop has been used to in-
duce constipation in a variety of studies to determine the
cause of constipation and identify novel compounds with
therapeutic effects [6,11,25]. Although the dose and time
for Lop treatment have varied among studies, constipation
was successfully induced by treatment with 1.5 – 3 mg/kg
body weight of Lop for 3–7 days [6,11,25,29,30]. In the
present study, we used Lop to induce constipation and
observed the human-like symptoms of constipation in SD
rats injected with 4 mg/kg of Lop without any specific
problems. Furthermore, Lop and racecadotril have been
successfully applied to decrease the risk of dehydration
and systemic or metabolic diseases such as diarrhea. Lo-
peramide is a mu-opiate-receptor agonist that extends the
orocecal and colonic transit times by increasing gut activ-
ity, disarranging electrical activity in the gut and delaying
the passage of fluid through the small intestine, although
it has some side effects such as severe allergic reaction,
toxic megacolon, constipation, decreased urination and
stomach bloating [31,32]. Racecadotril is an indirect delta
receptor agonist that accompanies antisecretory activity
without an increase of activity in gut muscle [33,34].
It should be noted that there are some limits and
restrictions to the clinical translation of results obtained
from Lop induced rats to human conditions, even
though the experimental procedure for rat models which
is easy and reproducible without negative side effects or
histologically detectable damages are widely used for the
evaluation and development of therapeutic drug [35].
Chronic constipation is categorized into three groups by
assessment of colonic transit and anorectal function;
normal transit or irritable bowel syndrome, pelvic floor
dysfunction (functional defecatory disorders) and slow
transit constipation [36]. Among patients with chronic
constipation, the most prevalent form is normal transit
(59%), followed by functional defecatory disorders (25%),slow transit (13%) and a combination of defecatory
disorders and slow transit (3%) [37]. However, models of
pharmacological constipation induced by Lop can only
simulate slow transit constipation showing less daily
fecal excretion, lower water content, lower numbers of
fecal pellets and thinner fecal mucus [23,29,38]. There-
fore, our results obtained from the Lop-induced consti-
pation model cannot completely translate all forms of
chronic constipation detected in human patients. Add-
itionally, further studies are needed to develop a novel
model of phenotypes of all classes of chronic constipa-
tion using genetic engineering technology and transient
injection of chemical substances.
Food intake and water consumption are considered to
be important factors for evaluation of constipation symp-
toms and therapeutic effects. However, Lop-induced con-
stipation models can have several different effects on food
intake and water consumption. In some cases, administra-
tion of Lop induces decreases in food intake and water
consumption [6], whereas some studies have shown that
Lop treatment does not induce any change in food intake
or water consumption [11]. In our study, food intake was
reduced in response to Lop administration, while water
consumption was maintained. These findings are in agree-
ment with those of a study conducted by Shimotoyodome
et al. [23], although the rate of decrease in food intake
differed among several studies. Furthermore, a variety of
responses regarding food intake and water consumption
in constipation models are induced by several herbal med-
icines and foods. Aqueous leaf extract of Aloe ferox Mill.
only induces enhancement of water consumption, whereas
food intake is consistently maintained without any signifi-
cant alteration [6]. In addition, food intake and water
consumption can be significantly decreased by the admin-
istration of Ficus carica paste for 4 weeks [11]. In the
present study, AEtLP treatment did not induce any signifi-
cant alteration of food intake or water consumption, al-
though a slight decrease in water consumption was
observed. These differences might be due to factors such
as the innate tastes of the herbal medicines and foods used
in each study.
A significant reduction in fecal excretion in Lop-induced
rats is considered one of the key markers of constipa-
tion in most constipation studies. Previously, stool-
related factors such as pellet number, weight, and water
content were shown to be dramatically decreased in rats
upon administration of Lop [6,10,11,29]. However, these
alterations were significantly recovered by plant extracts
with laxative effects. Aloe ferox Mill., a widely used medi-
cinal plant with healing properties, has been shown to im-
prove the number, water content, and weight of stools in
Lop-induced rats in a dose-dependent manner [6]. Fur-
thermore, leaf extracts of Mareya micrantha increased
stool output of rats relative to a control group at doses of
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effect on stool-related factors was observed in Lop +
AEtLP-treated rats (Figure 2).
Furthermore, histological studies have demonstrated
significant alterations in the intestines of constipation-
induced animals. The thickness of the distal colon layer
decreases significantly upon Lop treatment [11], and the
average thickness of the mucus layer is thinner in Lop-
treated rats than in control rats [23]. As shown in Figure 3,
similar results were observed in our study, such as de-
creases in crypt layer and muscle thickness in Lop-treated
SD rats, although the detection site differed between them
[11,23]. Furthermore, our data indicated that villus length
decreased significantly in the transverse colons of Lop-
induced constipated rats. These histological changes have
been shown to be recovered by herbal medicines and
foods having laxative effects. AEtLP treatment showed
similar results in the present study as those observed in
response to treatment with Ficus carica paste, which in-
duced increases in the thickness of the distal colon and
areas of crypt epithelial cells in a dose-dependent manner.
Specifically, the thickness of the crypt layer was restored
to that of the No-treated group [11].
Mucin is an important component of luminal mucus,
which protects the colorectal mucosa from a variety of
mechanical and chemical damage [39,40]. Secretion of
mucin is usually detected by staining with alcian blue at
pH 2.5. In this study, crypt epithelial cells and lumens
were strongly stained with alcian blue in No-treated rats
(Figure 3), which is agreement with the results of previ-
ous reports [23,41] and may validate the present his-
tochemical results. For example, Lop administration
induces reduction of mucin storage in crypt epithelial
cells by decreasing both the thickness and amount of the
luminal mucus layer [23]. Similar effects on mucin
secretion were detected in the present study. As shown
in Figure 3, the total level of mucin was significantly
reduced in Lop-treated SD rats, but was recovered
in Lop + AEtLP-treated rats. However, the amount of
mucin per crypt lumen was maintained in all groups.
Taken together, these findings indicate that one of the
main reasons for the decrease in total mucin was the
reduced thickness of the crypt layer.
mAChRs are a type of ACh receptor that mediate cho-
linergic signaling and are expressed on the surfaces of cer-
tain neurons and other cells, including heart and smooth
muscle cells [41,42]. These cells act as main receptors and
are activated by acetylcholine secreted from postgangli-
onic fibers in the parasympathetic nervous system.
Upon activation, signals are transferred to G protein-
receptor complexes via cytoplasmic domain interac-
tions, stimulating phospholipase c, which then cleaves
PIP2 into IP2 and DAG. The enhanced DAG then induces
the activation of PKC, which is involved in receptordesensitization, modulation of membrane structure events,
regulation of transcription, immune responses, regulation
of cell growth, and learning and memory [43,44]. mAChRs
are classified into five subtypes (M1-M5) according to
their tissue distribution and signal transduction mechan-
ism [45]. The role of these receptors has received great
attention as they have emerged as key therapeutic drugs
[46]. Among the five mAChR subtypes, M1, M2, and M3
significantly influence intestinal activity, including motility
and secretion [47]. mAChR M2 has the following indirect
function in cholinergic contraction: (1) mAChR M2
stimulation may reverse the relaxation of smooth muscle
induced by isoproterenol via inhibition of adenylate cy-
clase [24], (2) mAChR M2 stimulation may participate in
regulation of intracellular signaling originating from
mAChR M3 [24], and (3) mAChR M2 may play a role in
papillary dilation rather than papillary contraction as
suggested by studies of mAChR M2−/−M3−/− mice [48]. In
this study, we selected mAChR M2 and M3 as a target
protein to investigate the molecular mechanism behind
the laxative effects of AEtLP. We successfully detected the
level of mAChR M2 and M3 transcripts in the transverse
colon by RT-PCR as shown in previous studies, although
the origin of the samples and detection method used in
the analyses was not the same [47]. Furthermore, signifi-
cant alterations of the level of mAChR M2 transcripts
were observed under abnormal conditions, including
ischemia, neuropathic pain, arrhythmia, and diabetes
[49-52]. The results presented herein are the first to show
that the level of mAChR M2 and M3 transcripts dramatic-
ally increased in the transverse colon during AEtLP treat-
ment or Lop-induced constipation. These increases in
mAChR M2 and M3 transcripts were decreased by AEtLP
treatment. Furthermore, the expression pattern of PI-3K
and PKC in the down-stream signaling pathway was very
similar to that of mAChR M2 and M3. The increase in PI-
3 K and PKC expression induced by Lop administration
was inhibited by AEtLP treatment. Taken together, the
alteration of mAChR M2 and M3 signaling pathway ob-
served in the present study provide information that can
be used in future investigations of the causes of constipa-
tion and selection of targets for constipation treatment.
The Crypt of Lieberkühn is an intestinal gland located
in the epithelial lining of the small intestine and colon.
The crypt is composed of three major cell types, entero-
cytes, goblet cells, and paneth cells. Enterocytes are simple
columnar epithelial cells responsible for the digestion and
absorption of ions, sugars, peptides, amino acids, lipids,
vitamins, electrolytes, and water. Paneth cells are able to
secrete various enzymes, including sucrase and maltase,
along with enteropeptidase. Goblet cells are glandular,
simple, columnar epithelial cells that secrete mucin dis-
solved in water to form mucus with apocrine and mero-
crine patterns [53,54]. As shown in Figure 5, our results
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in the three crypt cells are tightly correlated with the pro-
gression and recovery of Lop-induced constipation. After
induction of constipation, lipid droplets containing mucin
accumulated in the cytoplasm of goblet cells and entero-
cytes, whereas abundant granules were present in paneth
cells. However, Lop + AEtLP treatment stimulated the
secretion of lipid droplets into the crypt lumen in both
goblet cells and enterocytes.
Conclusion
The results of this study suggest that AEtLP could
induce the recovery of stool number, water content, and
urine quantity while enhancing villus length, crypt layer,
and muscle thickness. In addition, these results provide
evidence that the laxative effects of AEtLP may be medi-
ated by the regulation of mAchRs and their downstream
signal as well as the secretion of lipid \droplets. Further-
more, these findings indicate that AEtLP could be
considered one of the therapeutic candidates for the
treatment of constipation, although many additional
studies are required to confirm this.
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